Table 1 Patient characteristics with respect to PCDH17 expression

Age, years

0.41

 Median

59

57

 Range

18–88

21–82

Sex (male/female)

54/32

38/49

0.01

WBC count, × 10⁹/L

< 0.0001

 Median

9.3

34

 Range

0.4–116.2

0.8–297.4

BM blasts, %

0.04

 Median

68.5

75

 Range

30–100

32–100

PB blasts, %

< 0.001

 Median

18

49

 Range

0–97

0–98

Karyotype

0.343

 Favorable

16

16

 Intermediate

46

55

 Adverse

23

14

 Unknown

1

2

FLT3-ITD

0.002

 Present

6

21

 Absent

80

66

NPM1

0.02

 Mutated

17

31

 Wild-type

69

56

CEBPA

1

 Single mutated

4

4

 Double mutated

2

3

 Wild-type

80

80

IDH1

0.28

 Mutated

10

6

 Wild-type

76

81

IDH2

0.82

 Mutated

8

9

 Wild-type

78

78

RUNX1

0.769

 Mutated

8

7

 Wild-type

78

80

DNMT3A

0.755

 Mutated

20

22

 Wild-type

66

65

TP53

0.005

 Mutated

12

2

 Wild-type

74

85

ERG expression^a

0.08

 High

37

49

 Low

49

38

BAALC expression^a

0.494

 High

45

41

 Low

41

46

MN1 expression^a

0.704

 High

44

42

 Low

42

45

WT1 expression^a

0.323

 High

40

47

 Low

46

40